Frazier Life Sciences Management, L.P. Crinetics Pharmaceuticals, Inc. Transaction History

Frazier Life Sciences Management, L.P.

  • $1.86 Billion
  • Q3 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024
SELL
$25.62 - $37.07 $30.6 Million - $44.2 Million
-1,192,448 Reduced 75.0%
397,483 $14.1 Million
Q3 2023

Nov 14, 2023
BUY
$15.97 - $30.59 $2.8 Million - $5.36 Million
175,108 Added 12.38%
1,589,931 $47.3 Million
Q1 2022

May 16, 2022
BUY
$17.15 - $28.31 $24.3 Million - $40.1 Million
1,414,823 New
1,414,823 $31.1 Million

Others Institutions Holding CRNX

# of Institutions
241
Shares Held
79.5M
Call Options Held
23.3K
Put Options Held
44.3K
View Full List

About Crinetics Pharmaceuticals, Inc.

CRNX Quotes by TradingView
  • Ticker CRNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 53,752,800
  • Market Cap $2.88B
  • Description
  • Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...
More about CRNX
Track This Portfolio

Track Frazier Life Sciences Management, L.P. Portfolio

Follow Frazier Life Sciences Management, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Frazier Life Sciences Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Frazier Life Sciences Management, L.P. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email